Media headlines about DelMar Pharmaceuticals (NASDAQ:DMPI) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DelMar Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.5157045398565 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of DelMar Pharmaceuticals in a research note on Thursday, October 5th.

DelMar Pharmaceuticals (NASDAQ:DMPI) opened at $1.57 on Monday. The stock has a market cap of $33.91, a P/E ratio of -2.28 and a beta of 0.91. DelMar Pharmaceuticals has a 52 week low of $0.78 and a 52 week high of $5.39.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its earnings results on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). research analysts predict that DelMar Pharmaceuticals will post -0.54 earnings per share for the current year.

In other news, CEO Saiid Zarrabian bought 60,900 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average cost of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

COPYRIGHT VIOLATION NOTICE: This report was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.